CoChat

Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip

Open access

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index; 18 of the 30 sources its claims cite were checked for support.

Abstract

Microphysiological systems (MPS) and Organs-on-Chips (OoCs) hold significant potential for replicating complex human biological processes in vitro. However, their widespread adoption by industry and regulatory bodies depends on effective qualification to demonstrate that these models are fit for purpose. Many models developed in academia are not initially designed with qualification in mind, which limits their future implementation in end-user settings. Here, we explore to which extent aspects of qualification can already be performed during early development stages of MPS and OoCs. Through a case study of our blood-perfused Vessel-on-Chip model, we emphasize key elements such as defining a clear context-of-use, establishing relevant readouts, ensuring model robustness, and addressing inherent limitations. By considering qualification early in development, researchers can streamline the progression of MPS and OoCs, facilitating their adoption in biomedical, pharmaceutical, and toxicological research. In addition, all in vitro methods must be independent of animal-derived materials to be considered fully fit for purpose. Ultimately, early qualification efforts can enhance the availability, reliability, and regulatory as well as ethical acceptance of these emerging New Approach Methodologies.

Overview

CoChat Summary

TL;DR

This case study argues that aspects of regulatory qualification can and should be considered during early development of microphysiological systems and Organs-on-Chips, using a blood-perfused Vessel-on-Chip model of microthrombosis as an example. It shows that readouts and robustness were already partly addressed, while context-of-use, limitations, and animal-derived materials remain key gaps for future fit-for-purpose qualification.

Key findings

  • Early qualification is feasible in academic MPS/OoC development: the Vessel-on-Chip already had relevant readouts and robustness checks, but its context-of-use was initially broad and implicit rather than clearly defined.
  • The model captures microthrombosis by platelet aggregation and fibrin formation on activated endothelium; positive controls used 10 ng/mL TNF-α, negative controls used EGM-2 medium, and anti-CD41 plus fluorescent fibrinogen were added 10 min before blood perfusion.
  • Robustness testing showed similar increased platelet and fibrin deposition across different endothelial cell sources with 10 ng/mL TNF-α; blood-donor variability was managed with thresholds of <2% culture area covered for negative controls and >4% coverage for positive controls before including donor data.
  • The model’s stated limitations include being endothelial-only, assessing only acute thrombosis with a maximum perfusion time of 30 minutes, and PDMS absorption of small hydrophobic molecules; animal-derived components such as heparin, antibodies, and rat tail collagen must be replaced for the model to be considered fully fit for purpose.

Methods

  • Case study mapping key qualification aspects—context-of-use, readouts, robustness, and limitations—onto prior development and application of a blood-perfused Vessel-on-Chip model.
  • The device is a PDMS microfluidic chip with four rectangular channels (14 mm × 300 μm × 50 μm; length × width × height) bonded to a PDMS-coated microscope slide; HUVECs or hiPSC-ECs were seeded at 15×10⁶ cells/ml in two steps to form an endothelial monolayer.
  • After endothelial treatment, recalcified human whole blood was perfused through the channels; platelet aggregation and fibrin deposition were visualized and quantified by fluorescence microscopy using fluorescently labelled anti-CD41 antibodies and fibrinogen.

Limitations

  • Paper-stated: the model lacks a well-defined context-of-use at early development; it is limited to endothelial cells and cannot account for tissue-resident immune cells or organ–organ interactions; it can only assess acute thrombotic effects with a maximum perfusion time of 30 minutes; PDMS absorbs small hydrophobic molecules; and animal-derived components introduce variability and prevent the model from being fully fit for purpose.
  • Paper-stated: donor age or gender could not be accessed due to donor service regulations, limiting prediction of donor-related variability.
  • Evident from the text: qualification aspects were mostly addressed implicitly and characterization data were split across publications; full qualification would require more data, standardization, and multi-stakeholder collaboration, and the SOP for fabrication and readout was still being drafted.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/ftox.2024.1513002

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Timeline of development of new approach methodologies. In early development, models are designed, extensively characterized up to proof-of-concept, which is used to start the qualification process. Qualification contains different aspects that have to be answered, before the model can be deemed fit-for-purpose within its context of use. Subsequently, a qualified model is implemented for its context of use, where it sees standardized use within biomedical, pharmaceutical, or toxicological settings. The central question that we try to answer is to which extent aspects of qualification can already be considered during early stages of model development.
FIGURE 1 Timeline of development of new approach methodologies. In early development, models are designed, extensively characterized up to proof-of-concept, which is used to start the qualification process. Qualification contains different aspects that have to be answered, before the model can be deemed fit-for-purpose within its context of use. Subsequently, a qualified model is implemented for its context of use, where it sees standardized use within biomedical, pharmaceutical, or toxicological settings. The central question that we try to answer is to which extent aspects of qualification can already be considered during early stages of model development.CC BY · PubMed Central
FIGURE 2 Overview of addressing aspects of qualification during early model development within the blood-perfused Vessel-on-Chip. (A) Photograph of the blood-perfused Vessel-on-Chip system, where blood is drawn by a syringe pump through the channels to create a physiological blood flow. (B) Typical morphological images of the endothelial monolayer in negative (top; EGM-2) and positive (bottom; 10 ng/mL TNF-α) conditions. Positive conditions show more elongated endothelial cells parallel to the flow direction. Scale bar, 100 µm. (C) Typical fluorescence microscopy images of platelet aggregation in negative and positive conditions. Positive conditions have elevated deposition of platelets (green) and fibrin (magenta). Scale bar, 100 µm. (D) Schematic of aspects of qualification that could be answered during early model development of the blood-perfused Vessel-on-Chip. For all criteria of qualification, certain aspects were found to already be addressed, mostly implicitly, in early development.
FIGURE 2 Overview of addressing aspects of qualification during early model development within the blood-perfused Vessel-on-Chip. (A) Photograph of the blood-perfused Vessel-on-Chip system, where blood is drawn by a syringe pump through the channels to create a physiological blood flow. (B) Typical morphological images of the endothelial monolayer in negative (top; EGM-2) and positive (bottom; 10 ng/mL TNF-α) conditions. Positive conditions show more elongated endothelial cells parallel to the flow direction. Scale bar, 100 µm. (C) Typical fluorescence microscopy images of platelet aggregation in negative and positive conditions. Positive conditions have elevated deposition of platelets (green) and fibrin (magenta). Scale bar, 100 µm. (D) Schematic of aspects of qualification that could be answered during early model development of the blood-perfused Vessel-on-Chip. For all criteria of qualification, certain aspects were found to already be addressed, mostly implicitly, in early development.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 5 Not valid · 7 Not checked · 37 Own results and interpretations

11 more claims · 1 with their cited sources checked

Create a free account to see all 64 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 39
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Citations

Cites

Show all 37 references

Research works printed but not linked: 5

  1. 2024, Innovative science and technology approaches for new drugs (ISTAND) pilot program, FDA
  2. 2016, Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches
  3. 2017, FDA’s predictive toxicology roadmap, U. S. Food Drug Adm.
  4. 2020, FDA’s Qualification process for drug development tools, U. S. Food Drug Adm.
  5. Leite, 2021, Resources for Organ-on-Chip validation and qualification - EUROoCS RAB’

Cited by

See all 10

Metadata

Authors
Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D.
Affiliations
University of Twente (NL)
Corresponding author
Weener, Huub J.
Venue
Frontiers in Toxicology
Published
2024-12-06
Volume
6
Pages
1513002-1513002
ISSN
2673-3080 (ISSN-L)
OpenAlex
W4405122965
Cited by
10
References
38
Citations by year
2026: 9 · 2025: 1
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Toxicology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Twente Research Information (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Innovative Medicines Initiative (853988)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
microphysiological systems, organ-on-a-chip, microvascular thrombosis, regulatory qualification, context of use, model robustness, readout, animal-derived materials, new approach methodologies, in vitro model, toxicology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip. https://app.cochat.ai/papers/10.3389/ftox.2024.1513002
The paper
Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D. (2024). Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2024.1513002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.